Salivary C-reactive protein among at-risk adolescents: A methods investigation of out of range immunoassay data

2018 ◽  
Author(s):  
Elizabeth Landau ◽  
John Arthur Trinder ◽  
Julian Simmons ◽  
Monika Raniti ◽  
Matthew Blake ◽  
...  
Keyword(s):  
At Risk ◽  
Temporal Stability ◽  
Management Technique ◽  
Clinical Settings ◽  
Diurnal Pattern ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Treatment Techniques ◽  
Salivary Biomarker ◽  
At Risk Adolescents

Inflammatory markers including C-Reactive Protein (CRP) are increasingly used within research and clinical settings. Yet, varying methodologies for cleaning immunoassay data with out of range (OOR) samples may alter characteristic levels of CRP, thereby obscuring interpretation and reliability. This study investigated the influence of eight immunoassay OOR data treatment techniques on salivary CRP (sCRP) samples from at-risk adolescents. Participants from the ‘Sleep and Education: learning New Skills Early’ (SENSE) Study were 86 adolescents at-risk for depression (50 female), aged 14.29 years (SD=1.04). ANOVA results showed no statistically significant differences in average morning (F(7, 590)=1.24, p=.28) and evening (F(7, 599)=1.29, p=.25) values produced by each OOR data cleaning technique. However, varying techniques produced differences in the magnitude of Pearson’s correlations between consecutive saliva samples (r’s between .27 – .78), and influenced the significance of a sCRP diurnal pattern; two techniques produced statistically higher morning than evening sCRP levels (t(85)=2.70, p=.01 and t(85)=2.67, p=.01), whereas six techniques failed to find statistical differences between morning and evening sCRP levels (p’s >.05). Varying techniques also produced statistically divergent associations between sCRP and age and depressive symptoms. Results from this study provide evidence for the temporal stability of sCRP among adolescents, show winsorization as an effective OOR data management technique, and highlight the influence of methodological decisions in cleaning salivary biomarker data and the need for consistency within the field.

scholarly journals Salivary C-reactive protein among at-risk adolescents: A methods investigation of out of range immunoassay data

2019 ◽  
Vol 99 ◽  
pp. 104-111 ◽  
Author(s):  
E.R. Landau ◽  
J. Trinder ◽  
J.G. Simmons ◽  
M. Raniti ◽  
M. Blake ◽  
...  
Keyword(s):  
At Risk ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
At Risk Adolescents

scholarly journals Novel Association of High C-Reactive Protein Levels and A69S at Risk Alleles in Wet Age-Related Macular Degeneration Women

2018 ◽  
Vol 9 ◽  
Author(s):  
Patricia Fernandez-Robredo ◽  
Sergio Recalde ◽  
Maria Hernandez ◽  
Javier Zarranz-Ventura ◽  
Blanca Molins ◽  
...  
Keyword(s):  
At Risk ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Risk Alleles ◽  
Age Related ◽  
Novel Association

scholarly journals C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

Circulation ◽  
2007 ◽  
Vol 115 (8) ◽  
pp. 981-989 ◽  
Author(s):  
Naveed Sattar ◽  
Heather M. Murray ◽  
Alex McConnachie ◽  
Gerard J. Blauw ◽  
Edward L.E.M. Bollen ◽  
...  
Keyword(s):  
At Risk ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Prospective Study ◽  
The Elderly ◽  
C Reactive Protein ◽  
Vascular Events ◽  
Reactive Protein

Abstract 874: MLN1202, a Novel CCR2 Antagonist, Decreases C-reactive protein in Patients at Risk for Atherosclerotic Cardiovascular Disease in a Double Blind Placebo Controlled study

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
M. Davidson ◽  
J. Lekstrom-Himes ◽  
J. Gilbert ◽  
D. Donaldson ◽  
Y. Lee ◽  
...  
Keyword(s):  
At Risk ◽  
Lipid Lowering ◽  
Smoking History ◽  
Controlled Study ◽  
C Reactive Protein ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Reactive Protein ◽  
Patients At Risk ◽  
Circulating Levels

Background: Macrophages play a central role in atherosclerotic plaque formation. The CC chemokine receptor 2 (CCR2), expressed on the surface of circulating monocytes, and its ligand MCP-1 (CCL2), are present in atherosclerotic plaques and may play a critical part in endothelial monocyte recruitment and activation. MLN1202 is a humanized monoclonal antibody with high specificity to CCR2, which interrupts MCP-1 binding to CCR2. MLN1202 is being developed for the treatment of immune mediated diseases. Hypothesis: We tested the hypothesis that MLN1202 significantly influences disease activity in patients at risk for ASCVD as measured by a reduction in circulating levels of high sensitivity C-reactive protein (hsCRP), an established biomarker of inflammation. Trial Design: In this double-blind placebo controlled study patients with at least 2 or more risk factors for ASCVD, no history or symptoms of ASCVD disease, and circulating levels of hsCRP > 3mg/L, were randomized 1:1 to receive a single infusion of 10 mg/kg MLN1202 (n 56) or placebo (n = 56). Subjects with hypercholesterolemia on stable doses of lipid-lowering agents were included. Circulating levels of hsCRP were determined every 2 weeks, and clinical examination performed every 4 weeks for 16 weeks following treatment. Results and Conclusion: Patients were recruited from nine centers in the US. The study population had a mean age of 60.9 years and included subjects with hypertension (59%), hypercholesterolemia (70%), significant smoking history (28%), and type 2 diabetes (16%). At screening the median value CRP was 6.8 mg/L with interquartile range from 4.7–9.3 mg/L. PK/PD results showed that the plasma level of MLN1202 required for > 90% receptor saturation was maintained for 6 to 8 weeks. A between-group difference in reduction of hsCRP was statistically significant from week 4 through week 8 following dosing. The maximum difference in absolute median reduction was observed at week 8 and it was 1.6 mg/L (p = 0.0275; Wilcoxon); the observed median percent reduction of hsCRP was 24.2% for MLN1202 group versus 2.5% increase for placebo group at 8 weeks (p = 0.0089; Wilcoxon). These data indicate that blockade of CCR2 reduces a biomarker related to inflammation in patients at risk for ASCVD.

scholarly journals Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus

2020 ◽  
Author(s):  
Hsi-en Ho ◽  
Michael J Peluso ◽  
Colton Margus ◽  
Joao Pedro Matias Lopes ◽  
Chen He ◽  
...  
Keyword(s):  
At Risk ◽  
Human Immunodeficiency Virus ◽  
Inflammatory Markers ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Markers Of Inflammation ◽  
Cell Counts ◽  
Immunodeficiency Virus ◽  
Factor Α ◽  
Necrosis Factor

Abstract We performed a retrospective study of coronavirus disease 2019 (COVID-19) in people with human immunodeficiency virus (PWH). PWH with COVID-19 demonstrated severe lymphopenia and decreased CD4+ T cell counts. Levels of inflammatory markers, including C-reactive protein, fibrinogen, D-dimer, interleukin 6, interleukin 8, and tumor necrosis factor α were commonly elevated. In all, 19 of 72 hospitalized individuals (26.4%) died and 53 (73.6%) recovered. PWH who died had higher levels of inflammatory markers and more severe lymphopenia than those who recovered. These findings suggest that PWH remain at risk for severe manifestations of COVID-19 despite antiretroviral therapy and that those with increased markers of inflammation and immune dysregulation are at risk for worse outcomes.

Sign in / Sign up

Export Citation Format

Share Document